Aug. 13: The FDA granted approval to Eylea (aflibercept) as a prefilled syringe. The Regeneron Pharmaceuticals, Inc. product is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. Dosing varies depending on the indication. The vascular endothelial growth factor (VEGF) inhibitor also is available in a single-dose vial. According to website Drugs.com, the price of a 40 mg/mL vial is more than $1,900. Visit www.eylea.com.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.